Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
599 clinical trials found
Clinical trials

CEC-4/CEL

A phase IIb, double-blind, randomised, placebo-controlled trial evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet (ISRCTN79155276)

Currently recruiting

CECI830A12101

An open-label, multi-center, phase I/II study of ECI830 as a single agent and in combination with ribociclib and endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors (NCT06726148)

Currently recruiting

CELEBRATE

A Phase 1B study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF-mutant metastatic melanoma (The CELEBRATE study) (NCT04720768)

No longer recruiting

Celldex CDX0159-13

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment [EMBARQ – CSU2] (NCT06455202)

The CDX0159-13 study is designed to evaluate the safety and efficacy of Barzolvolimab in adult participants with chronic spontaneous urticaria (CSU) who still have symptoms despite H1-antihistamine treatment. Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both administered as injections under the skin (subcutaneous). The treatment period will be approximately 52 weeks with all participants moved to active treatment (receiving treatment drug) after Week 24.

Currently recruiting

CG_MAGIC

Continuous Glucose Monitoring to Achieve euGlycemia in Cystic Fibrosis (Trial Not Registered)

Currently recruiting

CHARM

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction (NCT02864953)

Currently recruiting

CHECK MATE 9DW

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma (NCT04039607)

Currently recruiting

Chugai DQB103CT

A PHASE IC, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, IMMUNOGENICITY, AND BIOLOGICAL EFFECTS OF DONQ52 IN CELIAC DISEASE PATIENTS WITH GLUTEN CHALLENGE (NCT05425446)

Currently recruiting

CIP 12-19 fMRI

Pilot study: A comparison of rehabilitation success following primary vs secondary targeted muscle re-innervation surgery using functional magnetic resonance imaging analysis in upper and lower extremity amputees (Trial Not Registered)

Currently recruiting

CJSB462B12201

A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) (NCT07047118)

This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
Currently recruiting

CL1-95035-001

A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP (NCT06188702)

Currently recruiting

CLB-4000-1-001

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B (ACTRN12625000204448)

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B
Currently recruiting

CLEAR B

An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B (ACTRN12623000841673)

Currently recruiting

CLN-619-001

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Immunoregulatory Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors (NCT05117476)

Currently recruiting

CLOU064C12306

A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib (NCT06846281)

Currently recruiting

CLOU064J12301

A randomized, double-blind, double-dummy, placebocontrolled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa (NCT06799000)

Currently recruiting

CLOU064M12301

A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines (NCT05976243)

No longer recruiting

CMBG453E12101

A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome (NCT04810611)

Currently recruiting

CML14 ASCENDENCE

ASCENDANCE - ASCiminib Evaluation in Newly diagnosed CML with Dasatinib to Augment response in Complex genomic Etiology (ACTRN12623001338651)

At the start of the trial, Patients will have genetic testing and all patients will then receive treatment with Asciminib monotherapy at 80mg daily for the first four weeks, while the genetic results are analysed. Patients are then split into high or standard risks groups based on their genetic results. Patients determined to be at standard risk will continue to receive 80mg daily Asciminib monotherapy while high risk patients will receive combination therapy of: 80mg of Asciminib daily and 50mg of Dasatinib daily. Overall treatment duration is upto 2 years.
Currently recruiting

COALA Study

COALA Trial: Changing Outcomes After Low Anterior resection in colorectal cancer by anal sphincter prehabilitation prior to reversal of ileostomy – a parallel explanatory (COALA-1) and pragmatic trial (COALA-2) (Trial registration pending)

Currently recruiting
6 7 8 9 10